Product Code: ETC10074052 | Publication Date: Sep 2024 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The Vietnam Filgrastim market is experiencing steady growth driven by an increasing prevalence of cancer and other conditions requiring chemotherapy, as well as a rise in the number of hematopoietic stem cell transplantations. Filgrastim, a recombinant human granulocyte colony-stimulating factor, is widely used to reduce the incidence of febrile neutropenia and support the immune system during cancer treatment. The market is characterized by the presence of key players such as Amgen and Teva Pharmaceuticals, who offer various formulations and dosages of Filgrastim injections. Government initiatives to improve healthcare infrastructure and access to advanced treatments are also contributing to market expansion. However, pricing pressures and competition from biosimilars pose challenges to market growth in Vietnam.
The Vietnam Filgrastim market is experiencing significant growth due to increasing incidences of cancer and other diseases requiring chemotherapy treatments. The market is witnessing a rise in the adoption of biosimilars, including Filgrastim, as a cost-effective alternative to branded drugs. With a growing number of pharmaceutical companies entering the market and expanding their product portfolios, competition is increasing, leading to price competitiveness and improved accessibility for patients. Additionally, the government`s focus on enhancing healthcare infrastructure and improving access to affordable medications presents opportunities for market expansion. Overall, the Vietnam Filgrastim market is poised for continued growth driven by the rising demand for oncology treatments and the shift towards biosimilar medications.
In the Vietnam Filgrastim market, challenges include limited awareness and understanding of the drug among healthcare professionals and patients, leading to underutilization. Additionally, there may be regulatory hurdles and pricing issues that could affect market growth and access to the medication. Competition from alternative treatment options and potential supply chain disruptions could also pose challenges in ensuring a steady availability of Filgrastim in the market. Overall, efforts to educate stakeholders, navigate regulatory requirements, address pricing concerns, and establish a reliable supply chain are crucial in overcoming these obstacles and expanding the market for Filgrastim in Vietnam.
The Vietnam Filgrastim market is primarily driven by the increasing prevalence of cancer and infectious diseases, as Filgrastim is commonly used to stimulate the production of white blood cells in patients undergoing chemotherapy or bone marrow transplants. Additionally, rising healthcare expenditure, improving healthcare infrastructure, and growing awareness about the benefits of Filgrastim in reducing the risk of infection in cancer patients are contributing to market growth. Moreover, the introduction of biosimilar Filgrastim products at lower costs is expanding market access and affordability for patients, further driving market demand. Government initiatives to enhance access to essential medicines and ongoing research and development efforts to improve the efficacy and safety profile of Filgrastim are also key factors fueling market growth in Vietnam.
Government policies in Vietnam related to the Filgrastim market include regulations by the Ministry of Health to control the import, distribution, and pricing of pharmaceutical products, including Filgrastim. The government has implemented measures to ensure the quality, safety, and efficacy of drugs, with specific guidelines for the registration and approval of biologic medicines like Filgrastim. Additionally, there are policies in place to promote the use of generic drugs to increase accessibility and affordability for patients. Companies looking to enter the Filgrastim market in Vietnam must adhere to these regulations and requirements set by the government to ensure compliance and market access.
The Vietnam Filgrastim market is expected to show steady growth in the coming years, driven by factors such as increasing prevalence of cancer and other chronic diseases requiring chemotherapy, as well as a growing awareness and adoption of biologics in the country`s healthcare system. The government`s focus on improving access to advanced medical treatments and the rising healthcare expenditure are also likely to contribute to the market`s expansion. Additionally, collaborations between international pharmaceutical companies and local players to introduce innovative Filgrastim products tailored to the Vietnamese market are anticipated to further fuel market growth. Overall, the Vietnam Filgrastim market is poised for a positive trajectory, with opportunities for market players to capitalize on the increasing demand for supportive care in cancer treatment and other indications.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Vietnam Filgrastim Market Overview |
3.1 Vietnam Country Macro Economic Indicators |
3.2 Vietnam Filgrastim Market Revenues & Volume, 2021 & 2031F |
3.3 Vietnam Filgrastim Market - Industry Life Cycle |
3.4 Vietnam Filgrastim Market - Porter's Five Forces |
3.5 Vietnam Filgrastim Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 Vietnam Filgrastim Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
3.7 Vietnam Filgrastim Market Revenues & Volume Share, By Indication, 2021 & 2031F |
4 Vietnam Filgrastim Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Vietnam Filgrastim Market Trends |
6 Vietnam Filgrastim Market, By Types |
6.1 Vietnam Filgrastim Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 Vietnam Filgrastim Market Revenues & Volume, By Drug Type, 2021- 2031F |
6.1.3 Vietnam Filgrastim Market Revenues & Volume, By Biologic, 2021- 2031F |
6.1.4 Vietnam Filgrastim Market Revenues & Volume, By Biosimilar, 2021- 2031F |
6.2 Vietnam Filgrastim Market, By Distribution Channel |
6.2.1 Overview and Analysis |
6.2.2 Vietnam Filgrastim Market Revenues & Volume, By Hospital pharmacies, 2021- 2031F |
6.2.3 Vietnam Filgrastim Market Revenues & Volume, By Retail pharmacies, 2021- 2031F |
6.2.4 Vietnam Filgrastim Market Revenues & Volume, By Online pharmacies, 2021- 2031F |
6.3 Vietnam Filgrastim Market, By Indication |
6.3.1 Overview and Analysis |
6.3.2 Vietnam Filgrastim Market Revenues & Volume, By Chemotherapy induced Neutropenia, 2021- 2031F |
6.3.3 Vietnam Filgrastim Market Revenues & Volume, By Chronic Neutropenia, 2021- 2031F |
6.3.4 Vietnam Filgrastim Market Revenues & Volume, By Others, 2021- 2031F |
7 Vietnam Filgrastim Market Import-Export Trade Statistics |
7.1 Vietnam Filgrastim Market Export to Major Countries |
7.2 Vietnam Filgrastim Market Imports from Major Countries |
8 Vietnam Filgrastim Market Key Performance Indicators |
9 Vietnam Filgrastim Market - Opportunity Assessment |
9.1 Vietnam Filgrastim Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 Vietnam Filgrastim Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
9.3 Vietnam Filgrastim Market Opportunity Assessment, By Indication, 2021 & 2031F |
10 Vietnam Filgrastim Market - Competitive Landscape |
10.1 Vietnam Filgrastim Market Revenue Share, By Companies, 2024 |
10.2 Vietnam Filgrastim Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |